Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement

Rituximab (RTX) is non-inferior to cyclophosphamide (CYC) followed by azathioprine (AZA) for remission-induction in severe ANCA-associated vasculitis (AAV), but renal outcomes are unknown. This is a post hoc analysis of patients enrolled in the Rituximab for ANCA-Associated Vasculitis (RAVE) Trial w...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Am Soc Nephrol
Главные авторы: Geetha, Duvuru, Specks, Ulrich, Stone, John H., Merkel, Peter A., Seo, Philip, Spiera, Robert, Langford, Carol A., Hoffman, Gary S., Kallenberg, Cees G.M., St. Clair, E. William, Fessler, Barri J., Ding, Linna, Tchao, Nadia K., Ikle, David, Jepson, Brett, Brunetta, Paul, Fervenza, Fernando C.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Nephrology 2015
Предметы:
Clinical Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4378104/
https://ncbi.nlm.nih.gov/pubmed/25381429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2014010046
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы